drugset / Trial / NCT07249372
DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 2 Study of DRP-104, a Glutamine Antagonist, in Patients with NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer following standard of care treatment with chemotherapy and immunotherapy.
Timeline
- Start
- 2026-01-14
- Primary completion
- 2027-10-31
- Completion
- 2028-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | sirpiglenastat | Small molecule | 145 mg | Subcutaneous |